Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some updates from the Phase III MOMENTUM trial (NCT04173494), highlighting the important role of momelotinib and its ability to improve anemia in patients with myelofibrosis (MF). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
